联合药物治疗慢性前列腺炎的疗效分析:附253例报告

Efficacy Analysis of Combination Drug Therapy for Chronic Prostatitis:Report of 253 Cases

目的：探讨联合药物治疗慢性前列腺炎的疗效。方法：按照美国国立卫生研究所（NIH）制定的慢性前列腺炎症状指数（CPSI）标准结合两杯判定试验（PPMT）及前列腺按摩液（EPS）常规检查对253例慢性前列腺炎患者进行NIH分类以及疗效判定。253例均应用喹诺酮类抗生素治疗2~4周并联合α受体阻滞剂及舍尼通治疗4~6周。结果：按NIH制定的CPSI分类,253例患者中Ⅱ型23例（9.1%）,ⅢA型109例（43.1%）,ⅢB型121例（47.8%）。治疗6周后根据CPSI评分判定疗效：治愈18.6%,显效45.5%,有效14.6%,无效21.3%,总有效率77.7%。治疗后平均白细胞数（WBC）为（5.4±1.6）个/高倍镜视野（HP）,与治疗前[（24.6±3.8）个/HP]比较,差异有统计学意义（P〈0.05）。23例Ⅱ型前列腺炎患者治疗后,PPMT结果显示,19例转为阴性,转阴率为82.6%。结论：CPSI是一种较好的疗效评价方法。联合应用喹诺酮类抗生素、α受体阻滞剂及舍尼通治疗前列腺炎的效果满意。

Objective：To explore the efficacy of combination drug therapy for chronic prostatitis.Methods：According to National Institute Health Chronic Prostatitis Syndrome Index（NIH-CPSI）combined with the pre-and post-massage test（PPMT）and expressed prostatic secretion（EPS）routine examination,the NIH classification and efficacy evaluation was conducted for 253 patients with chronic prostatitis.All the 253 cases were administered quinolone antibiotics for 2 to 4 weeks,and meanwhile were administered alpha blocker and prostat for 4 to 6 weeks.Results：According to NIH-CPSI,there were 23（9.1%）cases of typeⅡ,109（43.1%）cases of typeⅢ A and 121（47.8%）cases of typeⅢ B among the 253 patients.After 6weeks of treatment,the patients were evaluated by CPSI and the results showed that the curative rate,the remarkable effective rate,the improving rate,the ineffective rate,the total effective rate was 18.6%,45.5%,14.6%,21.3%,and 77.7%,respectively.The average WBC count in EPS was（5.4±1.6）/HP after the treatment,while it was（24.6±3.8）/HP before the treatment.And the difference was statistically significant（P〈0.05）.After the treatment,23 patients with chronic bacterial prostatitis underwent bacterial culture by using PPMT,19 of which turned negative with a turning negative rate of82.6%.Conclusions：NIH-CPSI is a reliable method for efficacy evaluation.The combination of drugs,including quinolone,alpha blockade and prostat,shows satisfactory effect for the treatment of chronic prostatitis.